Publication Name	World Journal of Clinical Cases
Manuscript ID	78776
Country	China

Received	2022-07-14 08:44
Peer-Review Started	2022-07-14 08:47
To Make the First Decision
Return for Revision	2022-08-01 08:47
Revised	2022-08-19 09:18
Second Decision	2022-09-23 03:26
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-09-23 08:47
Articles in Press	2022-09-23 08:47
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-09-18 09:55
Typeset the Manuscript	2022-10-17 13:43
Publish the Manuscript Online	2022-10-27 04:55

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Shu-Ying Zeng, Jin Yuan and Min Lv
ORCID	Author(s) ORCID Number Shu-Ying Zeng http://orcid.org/0000-0002-8298-9320
Funding Agency and Grant Number
Corresponding Author	Shu-Ying Zeng, CCST, MSc, PhD, Doctor, Department of Oncology, The First People's Hospital of Longquanyi District Chengdu, No. 39 Mudan Street, Jinjiang District, Chengdu 652532, Sichuan Province, China. 18982193611@163.com
Key Words	Lymphoepithelioma-like carcinoma; Non-small cell lung cancer; Immunotherapy; Sintilimab; Programmed death-1; Case report
Core Tip	Herein, we present the case of a lymphoepithelioma-like carcinoma (LELC) patient who was successfully treated with sintilimab combined with paclitaxel and carboplatin. Recent literature on LELC is also reviewed and discussed for future avenues for LELC research.
Publish Date	2022-10-27 04:55
Citation	Zeng SY, Yuan J, Lv M. Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report. World J Clin Cases 2022; 10(31): 11617-11624
URL	https://www.wjgnet.com/2307-8960/full/v10/i31/11617.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i31.11617

Full Article (PDF)	WJCC-10-11617.pdf
Full Article (Word)	WJCC-10-11617.docx
Manuscript File	78776_Auto_Edited-YLC-Wang TQ-JLW.docx
Answering Reviewers	78776-Answering reviewers.pdf
Audio Core Tip	78776-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	78776-Conflict-of-interest statement.pdf
Copyright License Agreement	78776-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	78776-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	78776-Language certificate.pdf
Peer-review Report	78776-Peer-review(s).pdf
Scientific Misconduct Check	78776-Bing-Chen YL-2.png
Scientific Editor Work List	78776-Scientific editor work list.pdf